Dr Husain on Developments in ALK+ NSCLC

News
Video
Conference|International Lung Cancer Congress

Hatim Husain, MD, discusses developments in ALK-positive non–small cell lung cancer.

Hatim Husain, MD, medical oncologist and assistant professor of medicine at Moores Cancer Center of the University of California, San Diego, discusses developments in ALK-positive non–small cell lung cancer.

Related Videos
Julia S. Wong, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Matthew Pierre Deek, MD
Bradford (Brad) S. Hoppe, MD, MPH
Michael Chuong, MD, FACRO,
Jiye Liu, MD
Mitchell Machtay, MD, associate dean, Clinical Cancer Research, professor, endowed Chair in Cancer Clinical Research, Department of Radiation Oncology, professor, Department of Medicine, Penn State College of Medicine
Biagio Ricciuti, MD
Related Content

FDA Grants Fast Track Designation to BI 764532 for ES-SCLC and Extrapulmonary NEC

October 3rd 2023

Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers

August 7th 2023

Takeda to Voluntarily Withdraw Mobocertinib for EGFR Exon 20 Insertion+ NSCLC

October 2nd 2023

Camidge and Cetnar Revisit ASCO 2023 Data in Lung Cancer

June 26th 2023

Hypofractionated and Conventionally Fractionated Radiotherapy Generate Similar QOL, Safety in Breast Cancer

October 2nd 2023

Revumenib Meets CR/CRh End Point in KMT2A-Rearranged Relapsed/Refractory AML/ALL

October 2nd 2023

FDA Grants Fast Track Designation to BI 764532 for ES-SCLC and Extrapulmonary NEC

October 3rd 2023

Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers

August 7th 2023

Takeda to Voluntarily Withdraw Mobocertinib for EGFR Exon 20 Insertion+ NSCLC

October 2nd 2023

Camidge and Cetnar Revisit ASCO 2023 Data in Lung Cancer

June 26th 2023

Hypofractionated and Conventionally Fractionated Radiotherapy Generate Similar QOL, Safety in Breast Cancer

October 2nd 2023

Revumenib Meets CR/CRh End Point in KMT2A-Rearranged Relapsed/Refractory AML/ALL

October 2nd 2023

FDA Grants Fast Track Designation to BI 764532 for ES-SCLC and Extrapulmonary NEC

October 3rd 2023

Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers

August 7th 2023

Takeda to Voluntarily Withdraw Mobocertinib for EGFR Exon 20 Insertion+ NSCLC

October 2nd 2023

Camidge and Cetnar Revisit ASCO 2023 Data in Lung Cancer

June 26th 2023

Hypofractionated and Conventionally Fractionated Radiotherapy Generate Similar QOL, Safety in Breast Cancer

October 2nd 2023

Revumenib Meets CR/CRh End Point in KMT2A-Rearranged Relapsed/Refractory AML/ALL

October 2nd 2023